Moreover, the non-uniform KRAS G12C nucleotide exchange rates within cancer cells may generate varied drug responses, whereas uniform silencing of KRAS via siRNA consistently induces a quiescent state, underscoring the role of target dynamics in shaping treatment heterogeneity.39 Here, KRAS is linked to cancer.